MK-677 Ibutamoren for Sale | Complete Growth Hormone Secretagogue Research Guide
Shop Our Top Compounds
MK-677 Ibutamoren for Sale | Complete Growth Hormone Secretagogue Research Guide
MK-677 Ibutamoren for Sale: The Complete Growth Hormone Secretagogue Research Guide
MK-677, also known as ibutamoren or ibutamoren mesylate, stands as one of the most extensively studied oral growth hormone secretagogues in modern biomedical research. Unlike traditional growth hormone–releasing peptides (GHRPs) that require injection, MK-677 is a non-peptide, orally active compound that mimics the action of ghrelin at the growth hormone secretagogue receptor (GHS-R1a). Since its development by Merck in the 1990s, researchers have investigated MK-677 across dozens of clinical trials examining its effects on growth hormone (GH) secretion, insulin-like growth factor I (IGF-1) levels, body composition, bone mineral density, sleep architecture, and neuroprotection.
For researchers seeking MK-677 Ibutamoren for sale, understanding the depth of published science behind this compound is essential to designing rigorous study protocols. This complete research guide compiles more than two decades of peer-reviewed findings—from early pharmacokinetic profiles to landmark randomized controlled trials—to provide a definitive resource for the scientific community. All compounds discussed are for research purposes only and are not for human consumption.
Whether your laboratory focuses on endocrine physiology, sarcopenia modeling, or GH-axis pharmacology, this guide covers what published literature reveals about MK-677‘s mechanism of action, key clinical data, comparative pharmacology, and practical research considerations. Explore Iron Peak Peptides’ catalog of MK-677 and related secretagogues to support your next investigation.
What Is MK-677 (Ibutamoren)? Molecular Profile and Pharmacology
Chemical Identity and Classification
MK-677 (ibutamoren mesylate) is a spiropiperidine-derived, non-peptide growth hormone secretagogue originally developed by Merck Research Laboratories. Its molecular formula is C₂₇H₃₆N₄O₅S (mesylate salt), with a molecular weight of approximately 624.77 g/mol. Unlike peptide-based GH secretagogues such as GHRP-6, GHRP-2, or Ipamorelin, MK-677 is orally bioavailable—a characteristic that has made it uniquely valuable for chronic-dosing research protocols.
Chemically classified as a ghrelin mimetic, MK-677 functions as a selective agonist of the growth hormone secretagogue receptor type 1a (GHS-R1a), the same receptor that endogenous ghrelin activates. However, MK-677 is structurally unrelated to ghrelin (a 28-amino acid peptide) and instead belongs to a class of small-molecule GHS-R1a agonists that can survive gastric degradation and achieve systemic bioavailability through oral administration.
Mechanism of Action: Ghrelin Receptor Agonism
The mechanism by which MK-677 elevates growth hormone levels involves a multi-layered interaction with the hypothalamic-pituitary axis:
GHS-R1a Binding — MK-677 binds with high affinity to GHS-R1a receptors on somatotroph cells in the anterior pituitary, directly stimulating GH release. Research has confirmed that this binding mimics the action of endogenous ghrelin (Copinschi et al., 1996).
Hypothalamic GHRH Amplification — Beyond direct pituitary action, MK-677 appears to enhance the release of growth hormone–releasing hormone (GHRH) from the hypothalamus, creating a synergistic stimulatory effect on GH pulse amplitude.
Somatostatin Suppression — Published data suggest MK-677 may reduce somatostatin tone, the primary inhibitory signal that restrains GH secretion. By decreasing somatostatin’s suppressive effect, MK-677 permits higher-amplitude GH pulses.
Preservation of Pulsatility — Unlike exogenous GH administration, which delivers a constant, non-physiological GH level, MK-677 preserves the endogenous pulsatile pattern of GH release. The landmark 12-month trial by Nass et al. (2008) confirmed that MK-677 enhanced pulsatile GH secretion in older adults over a full year, maintaining a physiologic secretory rhythm.
IGF-1 Axis Activation — The GH elevations produced by MK-677 stimulate hepatic production of IGF-1 and IGF-binding protein-3 (IGFBP-3). In the Svensson et al. (1998) study, serum IGF-1 increased approximately 40% in obese male subjects treated with 25 mg MK-677 daily for 8 weeks.
The net pharmacological effect is a sustained elevation of GH and IGF-1 levels into ranges comparable to those observed in younger populations—a characteristic that has driven extensive investigation into MK-677‘s potential as a research tool for studying age-related GH decline.
Pharmacokinetics and Oral Bioavailability
MK-677‘s oral bioavailability distinguishes it from injectable growth hormone–releasing peptides. Following oral administration in published research protocols, MK-677 demonstrates:
Rapid absorption with peak plasma concentrations reached within 1–2 hours
Long half-life of approximately 24 hours, permitting once-daily dosing in study designs
Sustained GH/IGF-1 elevation over 24-hour sampling periods
No requirement for injection, simplifying chronic administration protocols in clinical research settings
This pharmacokinetic profile makes MK-677 particularly well-suited for long-duration studies where sustained GH-axis stimulation is the research objective.
Key Research Findings: GH Secretion, IGF-1, and the Somatotropic Axis
Acute GH-Releasing Effects
The earliest clinical investigations of MK-677 established its potent acute effects on GH release. In a foundational 1996 study, Copinschi and colleagues administered MK-677 to healthy young men for seven days and recorded 24-hour GH profiles using frequent blood sampling. The results demonstrated significant increases in both peak GH concentrations and overall GH area-under-the-curve (AUC) values, with preserved pulsatile secretion patterns. Importantly, the study confirmed that MK-677‘s GH-releasing activity was maintained throughout the seven-day treatment period without significant tachyphylaxis (Copinschi et al., 1996).
Sustained IGF-1 Elevation in Chronic Dosing
One of the most clinically significant findings in MK-677 research is its ability to sustain IGF-1 elevations over extended treatment periods. Svensson et al. (1998) conducted a randomized, double-blind, placebo-controlled trial in 24 obese males treated with MK-677 25 mg daily for 8 weeks. Key findings included:
~40% increase in serum IGF-1 (P < 0.001 vs. placebo)
Significant increase in IGF-binding protein-3 (P ≤ 0.001 vs. placebo)
Sustained GH elevation at both 2-week and 8-week time points
No increase in serum or urinary cortisol at 2 and 8 weeks
These data established that MK-677 could drive persistent somatotropic axis activation without the cortisol elevations that might confound long-term research protocols.
12-Month Randomized Controlled Trial in Older Adults
The most extensive clinical investigation of MK-677 was the 12-month randomized controlled trial conducted by Nass and colleagues (2008), published in the Annals of Internal Medicine. This landmark study enrolled 65 healthy older adults (aged 60–81 years) and administered MK-677 25 mg daily or placebo for one year. The results demonstrated:
GH secretion increased to levels characteristic of young adults, with enhanced pulsatile release maintained throughout the 12-month period
Fat-free mass increased significantly in the MK-677 group
Body weight increased modestly in MK-677-treated subjects
Changes in bone mineral density consistent with increased bone remodeling were observed
Fasting glucose increased in some subjects, a finding consistent with known GH-axis effects on insulin sensitivity
This trial remains the gold standard for MK-677 chronic-dosing research and is widely cited in growth hormone secretagogue literature. It provided strong evidence that oral ghrelin mimetics can restore youthful GH secretory patterns over clinically meaningful timeframes.
GH-Deficient Adult Populations
Chapman et al. (1997) investigated MK-677 specifically in GH-deficient adults. This study demonstrated that oral administration of MK-677 significantly stimulated the GH/IGF-1 axis in selected GH-deficient adults. The findings suggested that MK-677‘s mechanism of action requires at least partial integrity of the hypothalamic-pituitary axis, as subjects with severe organic pituitary disease showed attenuated responses. This observation has important implications for researchers studying the compound’s site of action and its dependence on endogenous GHRH signaling.
Body Composition Research: Fat-Free Mass, Nitrogen Balance, and Metabolic Effects
Fat-Free Mass and Energy Expenditure
Research has consistently demonstrated that MK-677 administration produces anabolic shifts in body composition—a finding of particular interest to investigators studying sarcopenia, cachexia, and age-related muscle loss. The Svensson et al. (1998) trial reported:
Significant increases in fat-free mass measured by both dual-energy X-ray absorptiometry (DEXA) and four-compartment body composition models (P < 0.01 and P < 0.05, respectively)
Significant increase in basal metabolic rate at 2 weeks of treatment (P = 0.01)
No significant change in total or visceral fat during the 8-week treatment period
These findings indicate that the anabolic effects of MK-677-driven GH elevation preferentially increase lean tissue mass rather than adipose tissue, at least over the short-to-medium term.
Reversal of Diet-Induced Catabolism
In a pivotal 1998 study, Murphy and colleagues examined whether MK-677 could reverse the protein-catabolic effects of caloric restriction—a research question with direct relevance to wasting conditions. Using a double-blind, randomized, placebo-controlled crossover design, the investigators placed healthy volunteers on a calorie-restricted diet to induce negative nitrogen balance, then administered MK-677 25 mg daily.
The results were striking: MK-677 completely reversed the diet-induced negative nitrogen balance, restoring nitrogen equilibrium within days. This reversal was associated with increased GH and IGF-1 levels. The study concluded that MK-677‘s ability to counteract protein catabolism through GH-axis stimulation supports its investigation as a research tool for studying catabolic states (Murphy et al., 1998).
Hip Fracture Recovery Research
Bach et al. (2004) investigated MK-677‘s effects in elderly patients recovering from hip fracture—a population characterized by acute catabolism and functional decline. In this study, MK-677 treatment increased serum IGF-1 levels. However, the study reported uncertainty regarding whether clinically significant effects on physical function were achieved, highlighting the need for larger, longer-duration trials in this specific population. The research nonetheless demonstrated that MK-677 can elevate IGF-1 in acutely ill elderly subjects.
Bone Density and Skeletal Research
Bone Turnover Markers in Elderly Subjects
Multiple studies have investigated MK-677‘s effects on bone metabolism, making this one of the compound’s most thoroughly researched domains. Murphy et al. (1999) conducted a study examining MK-677‘s effects on markers of bone turnover in healthy and functionally impaired elderly adults. Oral administration of MK-677 significantly increased markers of bone turnover, suggesting enhanced bone remodeling activity.
In a parallel investigation, Svensson et al. (1998) reported that short-term MK-677 treatment in obese males increased markers of both bone resorption and bone formation. This dual effect—stimulating both the osteoclastic and osteoblastic arms of bone remodeling—is consistent with the known effects of GH/IGF-1 axis stimulation on skeletal tissue.
Combination Therapy with Alendronate
A particularly innovative 2001 study by Murphy and colleagues examined the combined effects of MK-677 and alendronate (a bisphosphonate) on bone turnover markers and bone mineral density in postmenopausal osteoporotic women. The rationale was that MK-677‘s bone-forming effects might complement alendronate’s anti-resorptive properties. The study found that the combination of MK-677 and alendronate produced changes in bone turnover markers consistent with enhanced bone formation while resorption was suppressed by alendronate. This combination approach represents a promising research direction for studying anabolic-antiresorptive skeletal strategies (Murphy et al., 2001).
Long-Term Bone Remodeling in the Nass et al. Trial
The 12-month Nass et al. (2008) trial also tracked bone mineral density changes. Over the year-long treatment period, MK-677-treated subjects showed changes in bone mineral density consistent with increased bone remodeling. While the study was not primarily powered to detect BMD changes as a primary endpoint, the observed bone remodeling activity supported findings from the shorter-term trials and suggested that longer treatment periods with MK-677 may be needed to detect net bone density improvements.
Sleep Architecture and Neuroendocrine Research
MK-677 and REM Sleep Enhancement
One of the most intriguing findings in MK-677 research concerns its effects on sleep architecture. Copinschi et al. (1997) conducted a study examining the effects of prolonged oral MK-677 treatment on sleep quality in both young and older adult subjects. The results revealed:
Nearly 50% increase in REM sleep duration in older adults treated with MK-677 (P < 0.05)
Significant decrease in REM latency (P < 0.02)
Increased Stage IV (deep) sleep duration in younger subjects
Improved overall sleep quality across age groups
These findings are noteworthy because GH secretion is intimately linked to sleep architecture—particularly slow-wave sleep—and age-related GH decline parallels age-related deterioration in sleep quality. The bidirectional relationship between GH-axis activity and sleep makes MK-677 a valuable research tool for investigating neuroendocrine contributions to sleep regulation.
Implications for Age-Related Sleep Disruption Research
The sleep data from Copinschi et al. (1997) suggest that ghrelin receptor activation with MK-677 may partially restore sleep patterns toward a more youthful profile. For researchers studying age-related sleep disruption, circadian endocrinology, or the relationship between GH secretion and sleep architecture, MK-677 offers a pharmacological tool that can modulate both systems simultaneously. This dual action—on the somatotropic axis and on sleep regulation—distinguishes MK-677 from exogenous GH administration, which does not act through ghrelin receptor pathways.
Neuroprotection and Cognitive Research
Amyloid Beta Pathology in Preclinical Models
Recent preclinical research has expanded MK-677‘s investigational profile into the neuroscience domain. Jeong et al. (2018) investigated MK-677 (designated MK-0677 in their study) in 5XFAD transgenic mice, an established animal model of Alzheimer’s disease-like amyloidosis. The results demonstrated that ghrelin receptor activation with MK-677:
Inhibited amyloid-β (Aβ) burden in brain tissue
Reduced neuroinflammation as measured by microglial and astrocytic activation markers
Attenuated neurodegeneration in hippocampal regions
These preclinical findings suggest that ghrelin receptor agonism may confer neuroprotective effects through mechanisms involving reduced amyloid pathology and neuroinflammatory signaling. However, these results are from animal models and their translational significance requires further investigation.
Clinical Alzheimer’s Disease Trial
In contrast to the promising preclinical data, a large-scale clinical trial by Sevigny et al. (2008) found that MK-677 25 mg administered daily was ineffective at slowing the rate of clinical progression in Alzheimer’s disease patients. Published in Neurology, this study highlighted the gap between preclinical amyloid-modifying effects and clinical outcomes in established AD. The study remains an important reference for researchers evaluating ghrelin receptor agonists as potential neuroprotective agents, as it demonstrates that preclinical promise does not always translate to clinical efficacy.
MK-677 vs. Other Growth Hormone Secretagogues: Comparative Pharmacology
Understanding how MK-677 compares to other growth hormone–releasing peptides is essential for researchers selecting the appropriate secretagogue for their study design.
MK-677 vs. Ipamorelin
Ipamorelin is a pentapeptide GH secretagogue that, like MK-677, acts through the GHS-R1a receptor. Key comparative differences include:
Parameter | MK-677 (Ibutamoren) | Ipamorelin |
|---|---|---|
Structure | Non-peptide small molecule | Pentapeptide |
Route | Oral | Subcutaneous injection |
Half-life | ~24 hours | ~2 hours |
GH Selectivity | Moderate (some prolactin elevation) | High (minimal prolactin/cortisol) |
Dosing Frequency | Once daily (oral) | Multiple daily injections |
Chronic Dosing Data | 12-month RCT available | Limited chronic data |
For long-duration research protocols requiring oral dosing, MK-677 offers clear practical advantages. For studies requiring highly selective GH stimulation without prolactin effects, Ipamorelin may be preferred. Researchers may also explore CJC-1295/Ipamorelin combinations for synergistic GH-axis stimulation through complementary receptor pathways.
MK-677 vs. GHRP-6 and GHRP-2
GHRP-6 and GHRP-2 are hexapeptide GH secretagogues that also activate GHS-R1a but differ from MK-677 in several respects:
Route of administration: GHRP-6 and GHRP-2 require subcutaneous or intravenous injection; MK-677 is orally active
Appetite stimulation: GHRP-6 produces substantial appetite stimulation through ghrelin-pathway activation; MK-677 produces moderate appetite effects; GHRP-2 produces the least appetite stimulation
Cortisol and prolactin: GHRP-6 and GHRP-2 can increase both cortisol and prolactin; MK-677 produces modest prolactin elevation but minimal cortisol effects in chronic dosing
Duration of action: MK-677‘s 24-hour half-life provides sustained GH-axis stimulation vs. the short-acting (15–60 minute) effects of GHRP-6/GHRP-2
MK-677 vs. Exogenous GH Administration
A critical distinction exists between MK-677 and direct recombinant GH (rhGH) administration:
Pulsatility: MK-677 preserves physiological GH pulse patterns; rhGH delivers a non-pulsatile bolus
IGF-1 regulation: MK-677‘s GH elevation is subject to endogenous negative feedback, potentially reducing the risk of supraphysiological IGF-1 levels
Route: MK-677 is oral; rhGH requires daily injection
Cost: MK-677 research-grade material is substantially less expensive than pharmaceutical rhGH
Sigalos and Pastuszak (2017) published a comprehensive review of growth hormone secretagogue safety and efficacy in Sexual Medicine Reviews, concluding that GH secretagogues including MK-677 represent a pharmacologically distinct approach to GH-axis modulation with potential advantages over exogenous GH in select research contexts.
Research Applications and Study Design Considerations
Current Research Domains
Published literature supports the use of MK-677 as a research tool in the following investigational domains:
Age-related GH decline (somatopause): Nass et al. (2008) demonstrated MK-677 can restore GH secretion to youthful levels over 12 months
Body composition and sarcopenia modeling: Multiple studies show increases in fat-free mass and reversal of nitrogen catabolism
Bone metabolism and osteoporosis: Bone turnover markers consistently increase with MK-677; combination with bisphosphonates shows complementary effects
Sleep physiology: REM sleep enhancement documented in both young and older subjects
Neuroprotection: Preclinical evidence of anti-amyloid and anti-neuroinflammatory effects via ghrelin receptor activation
Metabolic research: Effects on glucose homeostasis, insulin sensitivity, and appetite regulation through GHS-R1a pathways
Study Design Notes for Researchers
Based on the published clinical trial literature, researchers designing MK-677 protocols should note:
Standard investigational dose: In published studies, researchers administered 25 mg orally once daily—the dose used in the majority of published clinical trials
Treatment duration: Acute effects are observable within days, but meaningful body composition and bone changes require 2–12 months of administration
Monitoring parameters: Studies routinely measured GH profiles (24-hour sampling), IGF-1, IGFBP-3, fasting glucose, insulin, body composition (DEXA), bone turnover markers, prolactin, and cortisol
Known metabolic effects: MK-677 may affect glucose homeostasis; fasting glucose and oral glucose tolerance should be monitored in research protocols
Appetite effects: MK-677 activates ghrelin pathways and may increase appetite in research subjects—a factor that should be accounted for in study design
Researchers looking to buy MK-677 online for investigational use should ensure they source from suppliers providing verified purity certificates and third-party analytical testing. Iron Peak Peptides provides research-grade MK-677 with full quality assurance documentation.
Published Research Studies and Citations
The following peer-reviewed studies form the evidence base for MK-677/ibutamoren research. All citations reference indexed publications accessible through PubMed and major scientific databases.
1. Copinschi G, Van Onderbergen A, L’Hermite-Balériaux M, et al. “Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men.” Journal of Clinical Endocrinology & Metabolism, 81(8):2776-2782, 1996. DOI: 10.1210/jcem.81.8.8768828
2. Copinschi G, Leproult R, Van Onderbergen A, et al. “Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man.” Neuroendocrinology, 66(4):278-286, 1997. DOI: 10.1159/000127249
3. Chapman IM, Pescovitz OH, Murphy G, et al. “Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults.” Journal of Clinical Endocrinology & Metabolism, 82(10):3455-3463, 1997. DOI: 10.1210/jcem.82.10.4297
4. Svensson J, Lönn L, Jansson JO, et al. “Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.” Journal of Clinical Endocrinology & Metabolism, 83(2):362-369, 1998. DOI: 10.1210/jcem.83.2.4539
5. Murphy MG, Plunkett LM, Gertz BJ, et al. “MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism.” Journal of Clinical Endocrinology & Metabolism, 83(2):320-325, 1998. DOI: 10.1210/jcem.83.2.4551
6. Svensson J, Ohlsson C, Jansson JO, et al. “Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone resorption and formation.” Journal of Bone and Mineral Research, 13(7):1158-1166, 1998. DOI: 10.1359/jbmr.1998.13.7.1158
7. Murphy MG, Weiss S, McClung M, et al. “Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults.” Journal of Endocrinology, 162(1):107-113, 1999. DOI: 10.1677/joe.0.1620107
8. Murphy MG, Bach MA, Plotkin D, et al. “Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.” Journal of Clinical Endocrinology & Metabolism, 86(3):1116-1125, 2001. DOI: 10.1210/jcem.86.3.7294
9. Bach MA, Rockwood K, Zetterberg C, et al. “The effects of MK-0677, an oral growth hormone secretagogue, in patients with hip fracture.” Journal of the American Geriatrics Society, 52(4):516-523, 2004. DOI: 10.1111/j.1532-5415.2004.52156.x
10. Nass R, Pezzoli SS, Oliveri MC, et al. “Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.” Annals of Internal Medicine, 149(9):601-611, 2008. DOI: 10.7326/0003-4819-149-9-200811040-00003
11. Sevigny JJ, Ryan JM, van Dyck CH, et al. “Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial.” Neurology, 71(21):1702-1708, 2008. DOI: 10.1212/01.wnl.0000335163.88054.e7
12. Sigalos JT, Pastuszak AW. “The Safety and Efficacy of Growth Hormone Secretagogues.” Sexual Medicine Reviews, 5(2):227-234, 2017. DOI: 10.1016/j.sxmr.2017.01.004
13. Jeong YO, Shin SJ, Park JY, et al. “MK-0677, a Ghrelin Agonist, Alleviates Amyloid Beta-Related Pathology in 5XFAD Mice, an Animal Model of Alzheimer’s Disease.” International Journal of Molecular Sciences, 19(6):1800, 2018. DOI: 10.3390/ijms19061800
14. Lee J, Kwon A, Chae HW, et al. “Effect of the Orally Active Growth Hormone Secretagogue MK-677 on Somatic Growth in Rats.” Yonsei Medical Journal, 59(10):1174-1180, 2018. DOI: 10.3349/ymj.2018.59.10.1174
15. Cardaci TD, Machek SB, Wilburn DT, et al. “LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: a case report.” Journal of Applied Physiology, 133(4):900-912, 2022. DOI: 10.1152/japplphysiol.00370.2022
Frequently Asked Questions About MK-677 Research
What does MK-677 do in research settings?
In published research studies, MK-677 (ibutamoren) functions as an oral ghrelin receptor agonist that stimulates growth hormone (GH) release from the pituitary gland. When researchers administered MK-677 to study subjects, it produced sustained elevations in GH and IGF-1 levels. Published trials have documented effects on body composition (increased fat-free mass), bone turnover markers, sleep architecture, and nitrogen balance. All published investigations use MK-677 for research purposes only.
How does MK-677 compare to Ipamorelin in research?
MK-677 and Ipamorelin are both growth hormone secretagogues that act through the GHS-R1a receptor, but they differ significantly. MK-677 is a non-peptide, orally active compound with a ~24-hour half-life, making it suitable for once-daily oral dosing protocols. Ipamorelin is a pentapeptide requiring subcutaneous injection with a ~2-hour half-life. Research indicates Ipamorelin produces more selective GH release with minimal prolactin or cortisol elevation, while MK-677 produces modest prolactin increases. The choice between them depends on study design requirements—oral convenience vs. injection selectivity. Explore both MK-677 and Ipamorelin in IronPeak’s research catalog.
What have MK-677 growth hormone studies shown?
The most comprehensive MK-677 growth hormone study is the 12-month randomized controlled trial by Nass et al. (2008), published in the Annals of Internal Medicine. In that study, daily oral administration of 25 mg MK-677 to healthy older adults (aged 60–81) increased GH secretion to levels characteristic of young adults, with enhanced pulsatile GH release maintained over the entire 12-month period. Earlier studies by Copinschi et al. (1996) and Svensson et al. (1998) confirmed acute GH elevation and ~40% increases in IGF-1 with MK-677 administration.
Is MK-677 the same as a peptide?
No. Despite being frequently discussed alongside growth hormone–releasing peptides, MK-677 is chemically classified as a non-peptide small molecule. While GHRPs like GHRP-6, GHRP-2, and Ipamorelin are peptide-based compounds requiring injection, MK-677 is a spiropiperidine derivative that is orally bioavailable. It acts on the same ghrelin receptor (GHS-R1a) as peptide-based secretagogues but through a non-peptide molecular scaffold. Refer to our Peptide Glossary for more information on peptide classification.
What MK-677 bone density research has been published?
Multiple studies have investigated MK-677‘s effects on bone. Murphy et al. (1999) demonstrated that MK-677 increased bone turnover markers in elderly adults. Svensson et al. (1998) showed increased markers of both bone resorption and formation. Murphy et al. (2001) examined MK-677 in combination with alendronate in postmenopausal osteoporotic women, finding complementary effects on bone turnover. The 12-month Nass et al. (2008) trial showed bone mineral density changes consistent with increased remodeling.
Where can researchers buy MK-677 for investigation?
Researchers seeking high-purity MK-677 Ibutamoren for sale can obtain research-grade material from Iron Peak Peptides. All MK-677 products are supplied with quality assurance confirming purity, identity, and sterility. Iron Peak Peptides also offers related growth hormone secretagogues including Ipamorelin and CJC-1295/Ipamorelin for comparative research protocols.
Does MK-677 affect sleep in research studies?
Yes. Copinschi et al. (1997) published one of the most cited MK-677 sleep studies in Neuroendocrinology. In older adult subjects, MK-677 treatment produced a nearly 50% increase in REM sleep duration (P < 0.05) and significantly decreased REM latency (P < 0.02). In younger subjects, MK-677 increased Stage IV (deep) sleep. These findings link ghrelin receptor activation to sleep architecture regulation and represent an active area of neuroendocrine research.
What are the research-documented effects of MK-677 on appetite?
As a ghrelin receptor agonist, MK-677 activates the same receptor pathway that endogenous ghrelin uses to stimulate appetite. Published studies have documented increased appetite as a consistent finding in MK-677 research subjects. This appetite-stimulating effect is relevant for researchers studying cachexia, wasting syndromes, and appetite regulation. It also represents a confounding variable that must be controlled for in body composition studies.
Conclusion: MK-677 as a Research Tool for Growth Hormone Secretagogue Science
MK-677 (ibutamoren) represents one of the most extensively characterized oral growth hormone secretagogues in the published scientific literature. With more than two decades of peer-reviewed research spanning GH/IGF-1 axis pharmacology, body composition, bone metabolism, sleep architecture, and neuroprotection, MK-677 has established itself as a cornerstone research compound for investigators studying somatotropic physiology.
The breadth of published data—from acute GH-releasing studies through 12-month randomized controlled trials—provides researchers with a robust evidence base for designing new protocols. Whether investigating age-related GH decline, catabolic conditions, skeletal metabolism, or ghrelin receptor pharmacology, MK-677 offers unique advantages as an orally active, long-acting, non-peptide GHS-R1a agonist.
For researchers ready to advance their investigations, Iron Peak Peptides offers verified, research-grade MK-677 Ibutamoren for sale alongside complementary secretagogues including Ipamorelin and CJC-1295/Ipamorelin. Explore the full growth hormone–releasing peptide research guide for comparative pharmacology, or visit the Peptide Glossary for comprehensive terminology.
Research Disclaimer
All information presented in this article is intended for educational and research purposes only. MK-677 (ibutamoren) is sold exclusively as a research compound and is not intended for human consumption, therapeutic use, or as a dietary supplement. The research findings described herein are drawn from published peer-reviewed literature and do not constitute medical advice, treatment recommendations, or dosage guidance for personal use. Researchers should consult applicable institutional guidelines, ethics boards, and regulatory requirements before conducting investigations with MK-677 or any growth hormone secretagogue. Iron Peak Peptides supplies research-grade compounds strictly for in vitro and legitimate scientific research applications. All products are labeled “For Research Use Only — Not For Human Consumption.”
🔬 Explore Research Peptides
- PEG-MGF 2mg — $55.00
- Cagrilintide 10mg — $89.00
- IPP-1 SM 10mg — $60.00
- Glutathione 1500mg — $59.00
